Clinical trials · Washington, D.C., DC
Epithelial Ovarian Cancer clinical trials in Washington, D.C.
We’re tracking 28 recruiting epithelial ovarian cancer studies with a site in or near Washington, D.C. — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Washington, D.C.
- NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Washington D.C., District of ColumbiaAges 18–60 - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Washington D.C., District of ColumbiaAges 18–99 - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Silver Spring, MarylandAges 18 years+ - NCT05281471RecruitingPhase 3
Tested drug for platinum-resistant ovarian cancer with bevacizumab
This Phase 3 trial tests a treatment made of an investigational gene-based drug plus standard “platinum” chemotherapy and bevacizumab, compared with standard chemotherapy and bevacizumab. It’s for ovarian/fallopian tube/primary peritoneal cancers that have not responded to platinum chemotherapy or came back quickly.
Silver Spring, MarylandAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT07214779RecruitingPhase 3
New drug vs chemo for platinum-resistant ovarian cancer
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
Silver Spring, MarylandAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Bethesda, MarylandAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Rockville, MarylandAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Fairfax, VirginiaAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Fairfax, VirginiaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Fairfax, VirginiaAges 18 years+ - NCT07278336RecruitingPhase 1
Study of ABBV901 for ovarian cancer
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Fairfax, VirginiaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Fairfax, VirginiaAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
Fairfax, VirginiaAges 18 years+ - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Fairfax, VirginiaAges 18 years+ - NCT06906341RecruitingPhase 2
Relacorilant combo for gynecologic cancers
This trial tests a drug called relacorilant combined with different treatments for ovarian, fallopian tube, primary peritoneal, or endometrial cancers. It may help patients whose cancer has stopped responding to standard therapies.
Fairfax, VirginiaAges 18 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
Fairfax, VirginiaAges 18 years+ - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Fairfax, VirginiaAges 18 years+ - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Fairfax, VirginiaAges 18 years+ - NCT05005403RecruitingPhase 1
Testing azirkitug for lung, head/neck, and other solid cancers
This Phase 1 study tests how a new medicine (azirkitug) behaves in the body and how safe it is, given by IV infusion alone or with other cancer drugs. It may help people with several advanced solid tumor cancers, especially after standard treatments have stopped working.
Fairfax, VirginiaAges 18 years+ - NCT05080946RecruitingEarly Phase 1
Aspirin with chemotherapy to improve ovarian tumor immune features
This early-phase study tests whether adding aspirin to standard neoadjuvant chemotherapy can change immune (anti-tumor) features inside ovarian, fallopian tube, or peritoneal tumors. It may help doctors better understand which patients respond and how aspirin could make treatment work better.
Fairfax, VirginiaAges 18 years+ - NCT05804370RecruitingPhase 3
Gleolan to help surgeons find ovarian cancer during surgery
This Phase 3 study tests whether Gleolan (a medicine given before surgery) helps doctors better see ovarian, fallopian tube, or peritoneal cancer during an operation. It may help improve how well surgeons can remove visible tumor tissue during planned surgery.
Annapolis, MarylandAges 18 years+
Hear when a new Epithelial Ovarian Cancer trial opens near Washington, D.C., DC
We’ll email you when one opens near Washington, D.C., DC — at most once a week, no account needed, unsubscribe anytime.
Epithelial Ovarian Cancer trials in other cities
Where these studies are running near Washington, D.C.
Institutions with a site for the recruiting epithelial ovarian cancer studies listed above.
- Virginia Cancer Specialists · 7 studies
- Holy Cross Hospital · 4 studies
- Inova Schar Cancer Institute · 4 studies
- NEXT Oncology · 4 studies
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 3 studies
- Greater Baltimore Medical Center · 2 studies
- Luminis Health Anne Arundel Medical Center · 2 studies
- MedStar Georgetown University Hospital · 2 studies
What taking part in a epithelial ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there epithelial ovarian cancer clinical trials near Washington, D.C.?
- Yes. We're currently tracking 28 recruiting epithelial ovarian cancer studies with a site near Washington, D.C., each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a epithelial ovarian cancer study near Washington, D.C.?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Washington, D.C. to take part?
- Not necessarily. These studies have a site near Washington, D.C., but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a epithelial ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New epithelial ovarian cancer studies open near Washington, D.C. regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.